Biodexa Pharmaceuticals PLC (BDRX)

Every figure this model derived for BDRX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2023-12-31.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 0 PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities 2025-12-31
cash 8,534,000 CashAndCashEquivalents 2025-12-31
current assets 12,443,000 CurrentAssets 2025-12-31
current liabilities 6,129,000 CurrentLiabilities 2025-12-31
equity 11,405,000 Equity 2025-12-31
revenue 381,000 Revenue 2023-12-31
sbc 0 AdjustmentsForSharebasedPayments 2025-12-31

The ratios

The figures themselves rather than their scores — what somebody looking up BDRX on one particular measure came for.

RatioValue
current ratio2.03
current ratio reported2.03
revenue growth-45.49
revenue growth per share-45.49
sbc pct revenue0.0

What to be careful about

What this model itself distrusts about BDRX's figures. Written by the derivation as it ran, not added afterwards.